Sunshine Biopharma (SBFM) Cash & Equivalents: 2010-2025
Historic Revenue - Interest and Investment Income for Sunshine Biopharma (SBFM) over the last 1 years, with Dec 2010 value amounting to $207,624.
- Sunshine Biopharma's Cash & Equivalents fell 23.76% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 23.76%. This contributed to the annual value of $9.7 million for FY2024, which is 40.55% down from last year.
- As of Q4 2010, Sunshine Biopharma's Revenue - Interest and Investment Income stood at $207,624, which was up 91.98% from $108,148 recorded in Q3 2010.
- Sunshine Biopharma's 5-year Cash & Equivalents high stood at $41.7 million for Q2 2022, and its period low was $1.7 million during Q2 2021.
- Its 3-year average for Cash & Equivalents is $13.9 million, with a median of $12.2 million in 2024.
- In the last 5 years, Sunshine Biopharma's Cash & Equivalents skyrocketed by 16,522.83% in 2021 and then plummeted by 53.53% in 2023.
- Quarterly analysis of 5 years shows Sunshine Biopharma's Cash & Equivalents stood at $2.0 million in 2021, then surged by 967.22% to $21.8 million in 2022, then declined by 25.35% to $16.3 million in 2023, then crashed by 40.55% to $9.7 million in 2024, then decreased by 23.76% to $9.3 million in 2025.
- Its Revenue - Interest and Investment Income stands at $207,624 for Q4 2010, versus $108,148 for Q3 2010 and $16,291 for Q2 2010.